Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

Recruiting now

Conditions studied: Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Specific Antigen, Radical Prostatectomy

In brief

This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer. No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.

Key facts

Study ID

NCT07516886

Run by

Lithuanian University of Health Sciences

People needed

500

Starts

2024-01-22

Expected to finish

2039-07-01

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient is an adult biological male.
• Patient has morphologically confirmed and untreated prostate cancer.
• Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy.
• Patient is informed about this observational study and has signed the informed consent form.

You may not qualify if…

• Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation.
• Patient received neoadjuvant prostate cancer treatment.
• Patient is set to receive adjuvant treatment.
• Patient has any contraindications for the operation.

Where it is running

• Lithuanian University of Health Sciences Hospital Kaunas Clinics, Department of Urology — Kaunas, Kauno, Lithuania (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.